Psychedelic-medicine stocks drop after ecstasy’s rocky day at the FDA
Psychedelic-medicine stocks dropped sharply early Wednesday, a day after an independent panel of Food and Drug Administration advisers said the benefits of a MDMA-assisted therapy for post-traumatic stress disorder do not outweigh its risks.
